RCUS

Arcus is a binary clinical-stage story dressed up as a pipeline play. The economics are unambiguously pre-commercial: FY2025 revenue collapsed to $33M (down 35.3% YoY, almost entirely collaboration milestones from Taiho) against a $523M R&D budget and a $482M operating cash outflow that is nearly triple FY2024's $170M burn. Net loss was $353M, retained deficit has widened to -$1.49B, and net margin of -1,069.7% makes the headline 109.4x P/S meaningless — this stock is valued as an option on the pipeline, not on current financials. ROE of -55.9% and the steadily expanding share count (125M shares, up 18.4% YoY after two 2025 underwritten offerings raising ~$438M gross and a November raise of 15.8M shares at $18.25) confirm that public-market dilution is the operating model.

The pipeline news is genuinely mixed in a way the price ($28.80, up only 2.2% today) doesn't fully resolve. Casdatifan, the HIF-2 inhibitor, is the crown jewel: the ARC-20 100mg QD cohort showed a 45.2% cORR and 15.1-month mPFS at 17.9 months follow-up versus Merck belzutifan's LITESPARK-005 benchmark of just 5.6 months mPFS — a striking differential that, if it holds in the Phase 3 PEAK-1 study, would support a real franchise in late-line RCC. Taiho's October 2025 option exercise for casdatifan in Japan/Asia validates the molecule commercially. But two material setbacks weigh against this: STAR-221 (domvanalimab + chemo in upper GI) was discontinued in December 2025 for futility on the IDMC's interim OS readout, and the AstraZeneca-sponsored eVOLVE-RCC02 combination study paused recruitment in October 2025 after immune-mediated AEs. The next domvanalimab futility look (STAR-121 in 1L NSCLC) lands in 1H26 and is a real overhang.